ICU Medical (NASDAQ:ICUI) Sets New 1-Year High – Here’s Why

by · The Cerbat Gem

ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report)’s share price hit a new 52-week high on Monday . The stock traded as high as $162.85 and last traded at $157.1650, with a volume of 213542 shares. The stock had previously closed at $157.51.

Analyst Ratings Changes

Several research firms have commented on ICUI. KeyCorp decreased their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a report on Monday, April 27th. Zacks Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. BTIG Research assumed coverage on shares of ICU Medical in a report on Monday, June 15th. They set a “buy” rating and a $170.00 price target on the stock. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, ICU Medical presently has an average rating of “Buy” and an average target price of $168.40.

Get Our Latest Stock Report on ICU Medical

ICU Medical Stock Performance

The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The stock has a market cap of $3.94 billion, a price-to-earnings ratio of 85.32, a P/E/G ratio of 2.20 and a beta of 0.76. The company’s fifty day simple moving average is $140.76 and its two-hundred day simple moving average is $139.20.

ICU Medical (NASDAQ:ICUI – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. During the same quarter in the previous year, the business earned $1.72 EPS. The company’s quarterly revenue was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts forecast that ICU Medical, Inc. will post 6.51 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In related news, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director directly owned 7,960 shares of the company’s stock, valued at $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC purchased a new position in shares of ICU Medical in the 2nd quarter worth approximately $243,000. Reinhart Partners LLC. purchased a new stake in shares of ICU Medical during the second quarter valued at approximately $46,148,000. Bank of America Corp DE increased its position in shares of ICU Medical by 11.2% during the first quarter. Bank of America Corp DE now owns 331,739 shares of the medical instruments supplier’s stock valued at $42,844,000 after acquiring an additional 33,508 shares during the last quarter. Edgestream Partners L.P. bought a new stake in ICU Medical during the first quarter worth $965,000. Finally, Janus Henderson Group PLC boosted its position in ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after purchasing an additional 99,256 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Further Reading